ASCELIA PHARMA IS AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY
ABOUT US
Our mission is to improve the life expectancy and quality of life for people living with cancer.
Our strategy is to develop and make available to patients a portfolio of differentiated, underappreciated and de-risked product candidates addressing unmet medical needs in cancer and cancer-related diseases.
Product pipeline
Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.
Oncoral (in phase I) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.